Quanterix Corp (QTRX) Peer Comparison

$2.68

$-0.11 (-3.94%)

As on 26-Aug-2026 16:00EDT

Market cap

$141 Mln

Revenue (TTM)

$153 Mln

P/E Ratio

--

P/B Ratio

0.6

Div. Yield

0 %

Edit

	Quanterix Corp (QTRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	141	12,753	10,906	9,762	10,222
Revenue ($ Mln)	153	1,505	613	2,589	785
Net Profit ($ Mln)	-123.11	160.59	-188.05	222.40	41.54
Net Margin (%)	-80.29	10.67	-30.68	8.59	5.29
RoE (%)	-46.20	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.35	--	44.47	251.57
Price-To-Book	0.60	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Quanterix Corp (QTRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	153.33	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	87.93	483.98	127.96	1,245.50	384.30
Gross Profit	64.72	942.44	393.22	1,343.60	347.62
Operating Expenses	197.47	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-132.15	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-125.31	203.83	-192.83	350.40	52.15
Provision for Tax	-2.20	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-123.11	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Quanterix Corp (QTRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	237.21	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	32.04	210.18	135.71	2,116.80	705.49
Current Liabilities	50.37	233.78	102.33	961.30	132.66
Total Liabilities	418.77	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Quanterix Corp (QTRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	148.58	630.60	404.74	7,231.50	1,749.63
Current Assets	171.05	1,344.12	515.78	3,020.50	1,200.55
Total Assets	418.77	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	33.39	212.71	102.84	1,203.70	690.94
Net Current Assets	0.00	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Quanterix Corp (QTRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-77.24	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	50.23	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	-0.71	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Quanterix Corp (QTRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-30.60	11.76	-22.53	8.98	1.79
ROE (%)	-46.20	10.86	-28.10	3.04	1.97
ROA (%)	-26.92	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-49.77	13.63	-30.58	-5.99	9.87
Net Margin (%)	-80.29	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Quanterix Corp (QTRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	23.41	17.55	41.55	1.37	16.49
EBIT Growth (%)	-4.99	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	-74.63	8.72	-102.66	-30.32	400.42
EPS Growth (%)	-44.87	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-32.85	17.33	-12.65	2.19	2.16

Valuation Ratios

	Quanterix Corp (QTRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-2.78	68.93	-34.59	--	189.42
Price / Book Value	1.01	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-2.32	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Quanterix Corp (QTRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.03	0.01	0.00	0.06	0.01
Current Ratio	3.40	5.75	5.04	3.14	9.05
Quick Ratio	2.45	3.86	4.46	2.33	7.64
Interest Coverage	--	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Quanterix Corp (QTRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	14.57	12.65	22.67	17.06	20.09
Asset Turnover	0.34	0.74	0.59	0.24	0.26
Receivable days	81.81	46.54	60.95	65.39	72.41
Inventory Days	216.22	331.92	193.84	221.09	146.53
Payable days	50.69	26.16	60.19	37.02	29.05
Cash Conversion Cycle	247.34	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly